HAIAP News Bulletins

February 1, 2022

See complete Bulletin here

TOPIC 1.   News from HAIAP 

1.1) Olle Hansson Award to recognise significant people

The Olle Hansson Award was considered in the light of including posthumous awards to very significant people.  It was agreed that very exceptional significant people eg Amit Sengupta, Martin Khor, Uncle Idris Mohamed must be honoured.

It was agreed by the Olle Hansson Award selection committee that this could happen retrospectively so they would be honoured in the time they were living.

The OH Award has not been presented since 2008 so it was agreed that The Award should go to Amit Sengupta for 2018, and jointly to Martin Khor and Uncle Idris Mohamed for 2019.  The 2020 Award would recognise Azmi Hassali. Tributes to these special people will be part of the HAIAP 40 book launching ceremony.

1.2) The HAIAP 40 Book

The Zoom ceremony to launch the HAIAP 40 book will take place on April 7 (World Health Day) or May 23 (Olle Hansson Day) (2022) – depending when the book is ready and will include tributes to these wonderful people. The book will be available electronically but in addition some hard copies will be printed in collaboration with TWN and other organisations.

TOPIC 2.   COVID 19 updates.

It must be noted that new information continually emerges so it is difficult to remain up-to-date. However therapies that have been found to be of no use will remain inappropriate so a table of inappropriate treatments has been prepared. The monoclonal antibody group of medications are ‘of interest’ and some have been recommended but maybe not useful in practice due to cost.

Other information along with the necessary caveats. (Suggest looking at the documents in order)

2.1)  Medicines NOT FOR USE for COVID 19.

2.2). Treatment flowchart 13 January 2022

2.3). Nirmatrelivir / ritonavir (Paxlovid) – approved for treatment and to be available as generic. With the possible availability of Paxlovid and the huge number of drug interactions associated with this product it is crucial to ensure a treatment model that incorporates adequate medication history and drug interaction management will be critical. See 2.4.

2.4a). Liverpool table of drug interactions  (relevant to COVID-19 treatment related drugs)

2.4b) Emergency Use of ‘Paxlovid’ FACT SHEET See 2.4b attachment

2.5) Molnupiravir: medicines Patent Pool announced 27 Generic companies are licensed to produce this drug/  https://medicinespatentpool.org/news-publications-post/27-generic-manufacturers-sign-agreements-with-mpp-to-produce-molnupiravir

3.   TOPIC 3. Sharing

3.1) Time to get serious about an Asean NWFZ from Prof Chee Khoon Chan

3.2) COVID-19 patients and their management in a tertiary care centre in Nepal from Dr Kumud Kafle